PLC Medical Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. The company’s newest product, RenalGuard, is approved for sale in the European Union as a general fluid balancing device. In addition, PLC has received Notices of Allowances for four of its patent applications associated with its RenalGuard technology from the US Patent and Trademark Office.
The company announced today that it will demonstrate RenalGuard at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend the event.
The president and CEO of PLC Medical Systems, Mark Tauscher, said, “EuroPCR is one the premier international cardiovascular events of the year. Since RenalGuard could provide an important solution for patients with diminished kidney function undergoing cardiac imaging procedures, this conference gives us a strong opportunity to meet with global knowledge leaders, current and potential customers, and current and potential distributors.”
In addition, PLC will hold its first international distributor meeting. The company will use the meeting as an opportunity to further educate their distribution partners about the latest scientific findings on RenalGuard’s safety and efficacy. It hopes this will accelerate sales of RenalGuard in the countries where it is now being marketed. PLC has distribution agreements for RenalGuard covering the following countries: China, Taiwan, New Zealand, Austria, Belgium, Spain, Portugal, Italy, Netherlands, Russia and all of the former Soviet Republic nations.
For more information on the company, please visit www.plcmed.com.
Let us hear your thoughts below:
